SCHEMBL14675403

SCHEMBL14675403

O=CC1CCN(Cc2ccc(C(F)(F)F)cc2C(F)(F)F)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.44
KCNT1 Q5JUK3 1/20 0.41
KCNT2 Q6UVM3 1/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
UBE2M P61081 1/20 0.40
DCUN1D1 Q96GG9 1/20 0.40
FFAR1 O14842 3/20 0.40
MAOA P21397 1/20 0.40
KMT2A Q03164 1/20 0.40
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39
JAK3 P52333 1/20 0.39
ATM Q13315 1/20 0.39
EPHX2 P34913 1/20 0.39
TEAD1 P28347 1/20 0.39
MAOB P27338 2/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14676544 0.95 MAOA (0.42) NR1H2KCNT1KCNT2KDM4EALDH1A1
SCHEMBL14676322 0.92 FFAR1 (0.40) NR1H2KCNT1KCNT2KDM4EALDH1A1
SCHEMBL14676621 0.87 DAO (0.41) KCNT1KCNT2MAOAEPHX2MAOB
SCHEMBL14676489 0.86 NR1H2 (0.40) NR1H2KCNT1KCNT2FFAR1MAOA
SCHEMBL14677029 0.86 ALDH1A1 (0.46) NR1H2KCNT1KCNT2KDM4EALDH1A1
SCHEMBL14676071 0.84 KCNT1 (0.46) KCNT1KCNT2KMT2A
SCHEMBL6946133 0.82 NR1H2 (0.50) NR1H2KCNT1KCNT2KDM4EALDH1A1
SCHEMBL28542707 0.82 KMT2A (0.59) KDM4EALDH1A1KMT2AATM
SCHEMBL14778314 0.82 FFAR1 (0.40) NR1H2KCNT1KCNT2FFAR1MAOA
SCHEMBL14676348 0.82 KCNT1 (0.42) KCNT1KCNT2MAOAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772277-B2 Nitrogen-containing heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-07-08 US disclosed
US-20130072467-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED 2013-03-21 US disclosed
WO-2013018929-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072467-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND ESRRA, ESRRB, ESR2 NR1H2 16/4885KCNT1 2957/4885KCNT2 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.